WallStreetZenWallStreetZen

NYSEMKT: NBY
Novabay Pharmaceuticals Revenue

OverviewEarningsRevenue
DividendOwnership
Novabay Pharmaceuticals revenue was $7.15M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q1 2025) ending on Mar 31, 2025 was $0.0, down 100% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, NBY annual revenue was $9.8M, with -6.4% growth year-over-year.

NBY past revenue growth

How has NBY's revenue growth performed historically?

Company
-11.9%
Industry
1,616.97%
Market
37.61%
NBY's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
NBY's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
NBY's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

NBY revenue history

Current Revenue
$7.2M
Current Earnings
$2.7M
Current Profit Margin
37.1%

Be the first to know when NBY announces revenue.

NBY Revenue History By Year

NBY Yearly RevenueNBY RevenueNBY ChangeNBY Revenue Growth
2024-12-31$9.78M-$674.00k-6.45%
2023-12-31$10.46M-$3.95M-27.42%
2022-12-31$14.40M$4.20M+41.16%
2021-12-31$10.20M$270.00k+2.72%
2020-12-31$9.93M$3.34M+50.54%
2019-12-31$6.60M-$5.91M-47.24%
2018-12-31$12.51M-$5.72M-31.39%
2017-12-31$18.23M$6.33M+53.23%
2016-12-31$11.90M$7.52M+171.56%
2015-12-31$4.38M$3.33M+315.65%
2014-12-31$1.05M-$2.42M-69.69%
2013-12-31$3.48M-$3.47M-49.95%
2012-12-31$6.95M-$4.07M-36.95%
2011-12-31$11.02M$1.27M+12.97%
2010-12-31$9.75M-$5.93M-37.81%
2009-12-31$15.68M$8.96M+133.32%
2008-12-31$6.72M$809.00k+13.68%
2007-12-31$5.91M$4.38M+285.71%
2006-12-31$1.53MN/AN/A
2005-12-31$0.00N/AN/A
2004-12-31$0.00N/AN/A

1 of 2

Novabay Pharmaceuticals Revenue FAQ

What was NBY's revenue last quarter?

On Invalid Date, Novabay Pharmaceuticals (NYSEMKT: NBY) reported Q1 2025 revenue of $0.00 up N/A year over year. In the same quarter last year, Novabay Pharmaceuticals's revenue was $0.00.

What was Novabay Pharmaceuticals's revenue in 2024?

Novabay Pharmaceuticals's annual revenue for the twelve months ending Dec 31, 2024 was $9.78 million, a 6.45% decrease year over year.

How much does Novabay Pharmaceuticals make in a day?

Based on Novabay Pharmaceuticals annual revenue for the past five years, NBY makes an average of $30,015.34 per day.

What was Novabay Pharmaceuticals's annual revenue growth in the past year?

As of Q3 2025, Novabay Pharmaceuticals's revenue has grown -11.9% year over year. This is 1,628.88 percentage points lower than the US Biotechnology industry revenue growth rate of 1,616.97%. Novabay Pharmaceuticals's revenue in the past year totaled $7.15 million.

How much does Novabay Pharmaceuticals make in a year?

Novabay Pharmaceuticals's revenue by year for the past five years is:
  • Novabay Pharmaceuticals's revenue for the twelve months ending Dec 31, 2024 was $9.78 million, a 6.45% decrease year over year.
  • Novabay Pharmaceuticals's annual revenue for Dec 31, 2023 was $10.46 million, a 27.42% decrease from 2022.
  • Novabay Pharmaceuticals's annual revenue for 2022 was $14.40 million, a 41.16% increase from 2021.
  • Novabay Pharmaceuticals's annual revenue for 2021 was $10.20 million, a 2.72% increase from 2020.
  • Novabay Pharmaceuticals's annual revenue for 2020 was $9.93 million, a 50.54% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.